Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 B cells.
性状
Liquid
IC50 & Target[1][2]
CD73
体外研究(In Vitro)
Mupadolimab induces the increased expression of markers associated with B cell maturation and antigen presentation, morphologic transformation to plasmablasts, and increased secretion of IgM and IgG. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: NSG-
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Miller R A, et al. Clinical results with a B cell activating anti-CD73 antibody for the immunotherapy of Covid-19. medRxiv, 2021.